Stock Research for MYL

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

MYL Stock Chart & Research Data

The MYL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MYL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MYL Due diligence Resources & Stock Charts

The MYL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MYL Detailed Price Forecast - CNN Money CNN View MYL Detailed Summary - Google Finance
Yahoo View MYL Detailed Summary - Yahoo! Finance Zacks View MYL Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View MYL Trends & Analysis - Trade-Ideas Barrons View MYL Major Holders - Barrons
NASDAQ View MYL Call Transcripts - NASDAQ Seeking View MYL Breaking News & Analysis - Seeking Alpha
Spotlight View MYL Annual Report - CompanySpotlight.com OTC Report View MYL OTC Short Report - OTCShortReport.com
TradeKing View MYL Fundamentals - TradeKing Charts View MYL SEC Filings - Bar Chart
WSJ View Historical Prices for MYL - The WSJ Morningstar View Performance/Total Return for MYL - Morningstar
MarketWatch View the Analyst Estimates for MYL - MarketWatch CNBC View the Earnings History for MYL - CNBC
StockMarketWatch View the MYL Earnings - StockMarketWatch MacroAxis View MYL Buy or Sell Recommendations - MacroAxis
Bullish View the MYL Bullish Patterns - American Bulls Short Pains View MYL Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View MYL Stock Mentions - StockTwits PennyStocks View MYL Stock Mentions - PennyStockTweets
Twitter View MYL Stock Mentions - Twitter Invest Hub View MYL Investment Forum News - Investor Hub
Yahoo View MYL Stock Mentions - Yahoo! Message Board Seeking Alpha View MYL Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for MYL - SECform4.com Insider Cow View Insider Transactions for MYL - Insider Cow
CNBC View MYL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MYL - OTC Markets
Yahoo View Insider Transactions for MYL - Yahoo! Finance NASDAQ View Institutional Holdings for MYL - NASDAQ


Stock Charts

FinViz View MYL Stock Insight & Charts - FinViz.com StockCharts View MYL Investment Charts - StockCharts.com
BarChart View MYL Stock Overview & Charts - BarChart Trading View View MYL User Generated Charts - Trading View




Latest Financial News for MYL


Mylan says Sanofi loses Lantus insulin patent claims
Posted on Thursday December 13, 2018

Sanofi is heavily reliant on Lantus, its leading product with sales of 4.62 billion euros ($5.26 billion) in 2017, and Mylan's own insulin drug would be its second competitor after Eli Lilly launched its version in late 2016. Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and paediatric patients with type 1 diabetes to control high blood sugar. Sanofi, which settled a similar case with Lilly in 2016, allowing it to launch Basaglar, sued Mylan in October 2017.


Should Warren Buffett — And You — Buy More TEVA Stock Right Now?
Posted on Thursday December 13, 2018

The last few years for drug-maker Teva Pharmaceuticals (NASDAQ:TEVA) haven’t exactly been that wonderful. TEVA stock has plunged on a series of mishaps and issues. In fact, TEVA has fallen enough that America’s favorite value investor, Warren Buffett, has taken a huge interest in the stock over the last few quarters.


Mylan says patent office cancels Sanofi's Lantus patents
Posted on Thursday December 13, 2018

Mylan N.V. said on Thursday the U.S. Patent and Trademark Office invalidated French drug company Sanofi's formulation patents on its blockbuster insulin drug Lantus, ruling in favor of the U.S. drugmaker. ...


Sanofi's Formulation Patents on Multibillion-Dollar Lantus® are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Posted on Thursday December 13, 2018

HERTFORDSHIRE, England and PITTSBURGH, Dec. 13, 2018 /PRNewswire/ -- Mylan N.V. (MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in its inter partes review (IPR) proceedings and found all claims of Sanofi's Lantus (insulin glargine 100 Units/mL) formulation patents (U.S. Patent Nos.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.